Showing 8011-8020 of 8720 results for "".
- Consensus: Straight-Line Vector Planning Produces Best Silhouette InstaLift Resultshttps://practicaldermatology.com/news/consensus-straight-line-vector-planning-produces-best-silhouette-instalift-results/2457668/Straight-line vector planning produces the ideal lifting effect and sets the stage for maximum collagen regeneration with the Silhouette InstaLift, according to a study in the July 2018 issue of Journal of Drugs in Dermat
- TruDerm Adds Second Dermatology Centerhttps://practicaldermatology.com/news/truderm-adds-second-dermatology-center/2457681/
- Game On: Head-to-head Trials to Enhance Competition in PsO Markethttps://practicaldermatology.com/news/head-to-head-trials-to-enhance-competition-in-pso-market/2457684/An increase in head-to-head trials will enhance the competition within the psoriasis market, according to
- AMSPA Merges with IALAhttps://practicaldermatology.com/news/amspa-merges-with-iala/2457688/The American Med Spa Association (AmSpa) is merging with the International Aesthetic and Laser Association, Inc. (IALA). The
- Dermatologists, Skin Cancer Survivors Tell "Skin Cancers, Take a Hike!"https://practicaldermatology.com/news/dermatologists-skin-cancer-survivors-tell-skin-cancers-take-a-hike/2457695/To help raise awareness of skin cancer prevention and detection, 12 dermatologists, skin cancer survivors, and their family and friends will tell “Skin Cancer, Take a Hike!” during a four-day trek through remote Alaska. Starting Sunday, July 15, the hikers will trek more than 20 miles
- XELJANZ Receives EU Marketing Authorization for Adults with Active PsAhttps://practicaldermatology.com/news/xeljanz-receives-eu-marketing-authorization-for-adults-with-active-psa/2457706/The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-mod
- FDA Approves Dermira's Qbrexza Cloth to Treat Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/fda-approves-delmiras-qbrexza-cloth-to-treat-primary-axillary-hyperhidrosis/2457709/The FDA has approved Qbrexza™ (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza is applied directly to the skin and is designed to block sweat production by inhib
- FDA Approves Braftovi in Combination with Mektovi for Advanced BRAF-mutant Melanomahttps://practicaldermatology.com/news/fda-approves-of-braftovi-in-combination-with-mektovi-for-advanced-braf-mutant-melanoma/2457710/The FDA has approved Array BioPharma Inc.'s BRAFTOVI (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by a
- Older Melanoma Patients May Have Better Response to Immune Checkpoint Blockade Therapyhttps://practicaldermatology.com/news/older-melanoma-patients-may-have-better-response-to-immune-checkpoint-blockade-therapy/2457728/Patient age correlates with response to immunotherapy in melanoma, and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute. Study resul
- Spironolactone May Be an Alternative to Antibiotics in Female Acnehttps://practicaldermatology.com/news/spironolactone-may-be-an-alternative-to-antibiotics-in-female-acne/2457738/The diuretic drug spironolactone may be just as effective as antibiotics for the treatment of women’s acne, report researchers from the Perelman School of Medicine at the University of Pennsylvania. The study, published in the Journal of